Redeye comments on Kancera reporting positive top-line results in its phase Ib/IIa KANDOVA study with KAND567 in ovarian cancer. Although the study was small and not placebo-controlled, we are encouraged by the signals. Earlier, we lowered our expectations for the study, but now we make upward adjustments to the program, leading to an increased valuation range.
LÄS MER
